Jan Klimas

List of Publications by Year
in descending order

52 papers	881 citations	516215 16 h-index	500791 28 g-index
53 all docs	53 docs citations	53 times ranked	1671 citing authors

#	Article	IF	Citations
1	Analysis of necroptosis and its association with pyroptosis in organ damage in experimental pulmonary arterial hypertension. Journal of Cellular and Molecular Medicine, 2022, 26, 2633-2645.	1.6	9
2	Physical activity enhances fecal lactobacilli in rats chronically drinking sweetened cola beverage. Open Life Sciences, 2022, 17, 686-694.	0.6	0
3	Isolated downregulation of HCN2 in ventricles of rats with streptozotocin-induced diabetic cardiomyopathy. BMC Cardiovascular Disorders, 2021, 21, 118.	0.7	7
4	Dapagliflozin elevates plasma high-density lipoprotein levels and influences visceral fat gene expression in streptozotocin-induced diabetes mellitus. Journal of Pharmacy and Pharmacology, 2021, 73, 778-784.	1.2	6
5	The protective effect of 1-methyltryptophan isomers in renal ischemia-reperfusion injury is not exclusively dependent on indolamine 2,3-dioxygenase inhibition. Biomedicine and Pharmacotherapy, 2021, 135, 111180.	2.5	5
6	Hematocrit-Related Alterations of Circulating microRNA-21 Levels in Heart Failure Patients with Reduced Ejection Fraction: A Preliminary Study. Genetic Testing and Molecular Biomarkers, 2021, 25, 302-306.	0.3	3
7	The tyrosine kinase inhibitor crizotinib influences blood glucose and mRNA expression of GLUT4 and PPARs in the heart of rats with experimental diabetes. Canadian Journal of Physiology and Pharmacology, 2021, 99, 635-643.	0.7	8
8	Vildagliptin improves vascular smooth muscle relaxation and decreases cellular senescence in the aorta of doxorubicin-treated rats. Vascular Pharmacology, 2021, 138, 106855.	1.0	9
9	Pioglitazone restores phosphorylation of downregulated caveolin-1 in right ventricle of monocrotaline-induced pulmonary hypertension. Clinical and Experimental Hypertension, 2021, , 1-12.	0.5	1
10	Alternative RAS in Various Hypoxic Conditions: From Myocardial Infarction to COVID-19. International Journal of Molecular Sciences, 2021, 22, 12800.	1.8	4
11	Effects of inorganic nitrate in a rat model of monocrotalineâ€induced pulmonary arterial hypertension. Basic and Clinical Pharmacology and Toxicology, 2020, 126, 99-109.	1.2	6
12	Disease severityâ€"related alterations of cardiac microRNAs in experimental pulmonary hypertension. Journal of Cellular and Molecular Medicine, 2020, 24, 6943-6951.	1.6	8
13	Hepatocyte growth factor plays a particular role in progression of overall cardiac damage in experimental pulmonary hypertension. International Journal of Medical Sciences, 2019, 16, 854-863.	1.1	8
14	Pegfilgrastim and linagliptin potentiate chemoattraction of Ccr2 and Cd44 stem cells accompanied by alterations of cardiac Hgf, Igf-1 and Mcp-1 in daunorubicin cardiomyopathy. Journal of Pharmacy and Pharmacology, 2019, 71, 1440-1450.	1.2	3
15	Opposite alterations of endothelin-1 in lung and pulmonary artery mirror gene expression of bone morphogenetic protein receptor 2 in experimental pulmonary hypertension. Experimental Lung Research, 2019, 45, 30-41.	0.5	4
16	Downregulation of myogenic microRNAs in sub-chronic but not in sub-acute model of daunorubicin-induced cardiomyopathy. Molecular and Cellular Biochemistry, 2017, 432, 79-89.	1.4	10
17	High glucose induces HGF-independent activation of Met receptor in human renal tubular epithelium. Journal of Receptor and Signal Transduction Research, 2017, 37, 535-542.	1.3	17
18	mRNA levels of circadian clock components Bmal1 and Per2 alter independently from dosing time-dependent efficacy of combination treatment with valsartan and amlodipine in spontaneously hypertensive rats. Clinical and Experimental Hypertension, 2017, 39, 754-763.	0.5	3

#	Article	IF	Citations
19	Daunorubicin Downâ€Regulates the Expression of Stem Cell Markers and Factors Involved in Stem Cell Migration and Homing in Rat Heart in Subchronic but not Acute Cardiomyopathy. Basic and Clinical Pharmacology and Toxicology, 2016, 119, 443-452.	1.2	5
20	Ramipril restores PPARÎ²/Î´ and PPARÎ³ expressions and reduces cardiac NADPH oxidase but fails to restore cardiac function and accompanied myosin heavy chain ratio shift in severe anthracycline-induced cardiomyopathy in rat. European Journal of Pharmacology, 2016, 791, 244-253.	1.7	23
21	Local and systemic reninâ€“angiotensin system participates in cardiopulmonaryâ€“renal interactions in monocrotaline-induced pulmonary hypertension in the rat. Molecular and Cellular Biochemistry, 2016, 418, 147-157.	1.4	16
22	Caffeine and cardiovascular diseases: critical review of current research. European Journal of Nutrition, 2016, 55, 1331-1343.	1.8	67
23	Perinatally administered losartan augments renal <scp>ACE</scp>2 expression but not cardiac or renal Mas receptor in spontaneously hypertensive rats. Journal of Cellular and Molecular Medicine, 2015, 19, 1965-1974.	1.6	96
24	Simvastatin impairs the induction of pulmonary fibrosis caused by a western style diet: a preliminary study. Journal of Cellular and Molecular Medicine, 2015, 19, 2647-2654.	1.6	5
25	<scp>l</scp>â€Arginine Attenuates Cardiac Dysfunction, But Further Downâ€Regulates Î±â€Myosin Heavy Chain Expression in Isoproterenolâ€Induced Cardiomyopathy. Basic and Clinical Pharmacology and Toxicology, 2015, 117, 251-260.	1.2	11
26	Impact of platelet phenotype on myocardial infarction. Biomarkers, 2015, 20, 17-25.	0.9	6
27	Bâ€type natriuretic peptide and heart failure: what can we learn from clinical trials?. Clinical and Experimental Pharmacology and Physiology, 2015, 42, 881-887.	0.9	1
28	Upregulation of SERCA2a following short-term ACE inhibition (by enalaprilat) alters contractile performance and arrhythmogenicity of healthy myocardium in rat. Molecular and Cellular Biochemistry, 2015, 403, 199-208.	1.4	8
29	Modulation of the QT interval duration in hypertension with antihypertensive treatment. Hypertension Research, 2015, 38, 447-454.	1.5	26
30	First Report on an Inotropic Peptide Activating Tetrodotoxin-Sensitive, â€œNeuronalâ€•Sodium Currents in the Heart. Circulation: Heart Failure, 2015, 8, 79-88.	1.6	4
31	Unbalanced upregulation of ryanodine receptor 2 plays a particular role in early development of daunorubicin cardiomyopathy. American Journal of Translational Research (discontinued), 2015, 7, 1280-94.	0.0	7
32	The utility of biomarker risk prediction score in patients with chronic heart failure. International Journal of Clinical and Experimental Medicine, 2015, 8, 18255-64.	1.3	11
33	Pioglitazone, a PPARÎ³ agonist, provides comparable protection to angiotensin converting enzyme inhibitor ramipril against adriamycin nephropathy in rat. European Journal of Pharmacology, 2014, 730, 51-60.	1.7	17
34	Enalaprilat increases PPARÎ²/Î´ expression, without influence on PPARÎ± and PPARÎ³, and modulate cardiac function in sub-acute model of daunorubicin-induced cardiomyopathy. European Journal of Pharmacology, 2013, 714, 472-477.	1.7	22
35	Glucose and blood pressure lowering effects of PycnogenolÂ® are inefficient to prevent prolongation of QT interval in experimental diabetic cardiomyopathy. Pathology Research and Practice, 2012, 208, 452-457.	1.0	16
36	Drug-Induced Cardiomyopathies. , 2012, , .		1

#	Article	IF	Citations
37	Discrepant Regulation of <scp>QT</scp> (<scp>QT</scp>c) Interval Duration by Calcium Channel Blockade and Angiotensin Converting Enzyme Inhibition in Experimental Hypertension. Basic and Clinical Pharmacology and Toxicology, 2012, 111, 279-288.	1.2	13
38	Enalapril decreases cardiac mass and fetal gene expression without affecting the expression of endothelin-1, transforming growth factor Î²-1, or cardiotrophin-1 in the healthy normotensive rat. Canadian Journal of Physiology and Pharmacology, 2011, 89, 197-205.	0.7	8
39	Heart rate correction of the QT duration in rats. European Journal of Pharmacology, 2010, 641, 187-192.	1.7	131
40	Pycnogenol^{Â®} improves left ventricular function in streptozotocinâ€induced diabetic cardiomyopathy in rats. Phytotherapy Research, 2010, 24, 969-974.	2.8	17
41	Isoproterenolâ€induced heart failure in the rat is associated with nitric oxideâ€dependent functional alterations of cardiac function. European Journal of Heart Failure, 2009, 11, 140-146.	2.9	90
42	Rapid large artery remodeling following the administration and withdrawal of calcium channel blockers in spontaneously hypertensive rats. European Journal of Pharmacology, 2009, 619, 85-91.	1.7	16
43	Effect of chronic nNOS inhibition on blood pressure, vasoactivity, and arterial wall structure in Wistar rats. Nitric Oxide - Biology and Chemistry, 2009, 20, 304-310.	1.2	15
44	Discrepancy between increased left ventricular mass and â€œnormalâ€•QRS voltage is associated with decreased connexin 43 expression in early stage of left ventricular hypertrophy in spontaneously hypertensive rats. Journal of Electrocardiology, 2008, 41, 730-734.	0.4	30
45	Prolonged QT Interval Is Associated with Blood Pressure Rather Than Left Ventricular Mass in Spontaneously Hypertensive Rats. Clinical and Experimental Hypertension, 2008, 30, 475-485.	0.5	21
46	Triadin is a critical determinant of cellular Ca cycling and contractility in the heart. American Journal of Physiology - Heart and Circulatory Physiology, 2007, 293, H3165-H3174.	1.5	11
47	Stress and high heart rate provoke ventricular tachycardia in mice expressing triadin. Journal of Molecular and Cellular Cardiology, 2007, 42, 962-971.	0.9	23
48	Increased expression of endothelial nitric oxide synthase and caveolin-1 in the aorta of rats with isoproterenol-induced cardiac hypertrophy. Canadian Journal of Physiology and Pharmacology, 2006, 84, 1245-1250.	0.7	16
49	Relation Between QRS Amplitude and Left Ventricular Mass in the Initial Stage of Exercise-Induced Left Ventricular Hypertrophy in Rats. Clinical and Experimental Hypertension, 2005, 27, 533-541.	0.5	16
50	The Initial Stage of Left Ventricular Hypertrophy in Spontaneously Hypertensive Rats is Manifested by a Decrease in the QRS Amplitude/Left Ventricular Mass Ratio. Clinical and Experimental Hypertension, 2004, 26, 557-567.	0.5	16
51	QRS Voltage-Duration Product in the Identification of Left Ventricular Hypertrophy in Spontaneously Hypertensive Rats. Arquivos Brasileiros De Cardiologia, 2002, 79, 143-148.	0.3	4
52	Potential Target Molecules in Diabetic Cardiomyopathy: Hepatocyte Growth Factor (HGF) and Ryanodine Receptor 2 (RyR2). , 0, , .		1